EPZM News and Press, Epizyme Inc. From 08/04/20

Epizyme, Inc. (EPZM) Q2 2020 Earnings Conference Call August 4, 2020, 8:30 am ET Company Participants Alicia Davis - IR, THRUST Strategic Communications Rob Bazemore - President & CEO Matt Ros - Chief Strategy & Business Officer Paolo Tombesi - CFO Shefali Agarwal - C...

Epizyme (NASDAQ: EPZM ) : Q2 GAAP EPS of -$0.58 misses by $0.01 . More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

TAZVERIK ® Approved for Multiple Cancer Indications; Executing Well on Commercial Launches for TAZVERIK in Epithelioid Sarcoma and Follicular Lymphoma Conference Call to be Held Today, August 4 at 8:30 a.m. ET Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage b...

Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business ...

Epizyme ( EPZM ) advanced from a clinical-stage company to a commercial stage company in January 2020 when Tazverik (tazemetostat) was approved by the FDA for advanced epithelioid sarcoma. Revenue from the sale of the drug was minimal in Q1 2020 but should ramp significantly over the next few ...

Insider buying more than doubled last week with insiders purchasing $286.95 million of stock compared to $123.37 million in the week prior even as the S&P 500 declined nearly 3% for the week. The large spike in COVID-19 cases in both Texas and Florida caught the attention of investors and ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Aptinyx Reports Completion of Enrolment in NYX-783 Trial Aptinyx ( APTX ) reported completion of enrollment in its NYX-783 trial. This phase 2 study aims to assess the safety and efficacy of NYX-783 in treating patients with post-traumatic stress disorder (PTSD). The company expects the ...

Epizyme (NASDAQ: EPZM) on Thursday announced that had it secured Food and Drug Administration approval for the drug Tazverik to be used in previously treated adults with follicular lymphoma and an EZH2 mutation, and in relapsed or refractory patients with no other treatment options. Back i...

Under accelerated review status, the FDA approves Epizyme's ( EPZM +4.5% ) Tazverik (tazemetostat) for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have receive...